Literature DB >> 18288880

NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Alireza Minagar1, Deborah Commins, J Steven Alexander, Romy Hoque, Francesco Chiappelli, Elyse J Singer, Behrooz Nikbin, Paul Shapshak.   

Abstract

The neurological complications of AIDS (NeuroAIDS) include neurocognitive impairment and HIV-associated dementia (HAD; also known as AIDS dementia and HIV encephalopathy). HAD is the most significant and devastating central nervous system (CNS) complications associated with HIV infection. Despite recent advances in our knowledge of the clinical features, pathogenesis, and neurobiological aspects of HAD, it remains a formidable scientific and therapeutic challenge. An understanding of the mechanisms of HIV neuroinvasion, CNS proliferation, and HAD pathogenesis provide a basis for the interpretation of the diagnostic features of HAD and its milder form, HIV-associated minor cognitive/motor disorder (MCMD). Current diagnostic strategies are associated with significant limitations, but it is hoped that the use of biomarkers may assist researchers and clinicians in predicting the onset of the disease process and in evaluating the effects of new therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288880     DOI: 10.1007/BF03256266

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  232 in total

Review 1.  Cerebrospinal fluid analysis for the diagnosis of human immunodeficiency virus-related neurologic diseases.

Authors:  T Weber
Journal:  Semin Neurol       Date:  1999       Impact factor: 3.420

2.  Relationship between viral load in blood, cerebrospinal fluid, brain tissue and isolated microglia with neurological disease in macaques infected with different strains of SIV.

Authors:  M Demuth; S Czub; U Sauer; E Koutsilieri; P Haaft; J Heeney; C Stahl-Hennig; V ter Meulen; S Sopper
Journal:  J Neurovirol       Date:  2000-06       Impact factor: 2.643

3.  Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients.

Authors:  R B Laing; P J Flegg; R P Brettle; C L Leen; S M Burns
Journal:  Int J STD AIDS       Date:  1996-07       Impact factor: 1.359

Review 4.  HIV pharmacology: barriers to the eradication of HIV from the CNS.

Authors:  Bryan McGee; Nathalie Smith; Francesca Aweeka
Journal:  HIV Clin Trials       Date:  2006 May-Jun

5.  Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry.

Authors:  O Bagasra; E Lavi; L Bobroski; K Khalili; J P Pestaner; R Tawadros; R J Pomerantz
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

6.  High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy.

Authors:  A De Milito; B Hejdeman; J Albert; S Aleman; A Sönnerborg; M Zazzi; F Chiodi
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-20       Impact factor: 2.205

7.  Validation of the HIV Dementia Scale in an elderly cohort of patients with subcortical cognitive impairment caused by subcortical ischaemic vascular disease or a normal pressure hydrocephalus.

Authors:  Barbera van Harten; Marise N J Courant; Philip Scheltens; Henry C Weinstein
Journal:  Dement Geriatr Cogn Disord       Date:  2004-04-14       Impact factor: 2.959

Review 8.  HIV-related movement disorders: epidemiology, pathogenesis and management.

Authors:  Francisco Cardoso
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

9.  Cerebrospinal fluid analysis in HIV-1-infected children: immunological and virological findings before and after AZT therapy.

Authors:  A M Laverda; P Gallo; A De Rossi; S Sivieri; P Cogo; A Pagliaro; L Chieco-Bianchi; B Tavolato
Journal:  Acta Paediatr       Date:  1994-10       Impact factor: 2.299

10.  Intrathecal IgG synthesis and albumin leakage are increased in subjects with HIV-1 neurologic disease.

Authors:  E J Singer; K Syndulko; B Fahy-Chandon; P Schmid; A Conrad; W W Tourtellotte
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-03
View more
  23 in total

1.  Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.

Authors:  A H Shin; H J Kim; S A Thayer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

3.  Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion.

Authors:  Ana Ayarza; Virginia Parisi; Javier Altclas; Daniela Visconti; Gabriel Persi; Carlos A Rugilo; Emilia M Gatto
Journal:  J Neurol       Date:  2009-02-28       Impact factor: 4.849

4.  Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

Authors:  John Douglas Hoekman; Rodney J Y Ho
Journal:  AAPS PharmSciTech       Date:  2011-04-26       Impact factor: 3.246

5.  [Treatment of neuro-AIDS on a neurological intensive care unit: epidemiology and predictors of outcome].

Authors:  O Braicks; K Anneken; D Reichelt; W R Schäbitz; R Dziewas; S Evers; I W Husstedt
Journal:  Nervenarzt       Date:  2011-10       Impact factor: 1.214

Review 6.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

Review 7.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

8.  An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China.

Authors:  Yulin Zhang; Luxin Qiao; Wei Ding; Feili Wei; Qingxia Zhao; Xicheng Wang; Ying Shi; Ning Li; Davey Smith; Dexi Chen
Journal:  J Neurovirol       Date:  2012-03-13       Impact factor: 2.643

9.  Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death.

Authors:  Hee Jung Kim; Kirill A Martemyanov; Stanley A Thayer
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

10.  Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures.

Authors:  Angela H Shin; Stanley A Thayer
Journal:  Mol Cell Neurosci       Date:  2012-12-23       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.